Newsquawk Logo

Trump administration indefinitely delayed BALANCE, a Medicare pilot to expand GLP-1 weight-loss drug coverage through private insurers, Axios reports

Importance
Level 1
  • Medicare will instead cover the drugs through a transitional programme from July until the end of 2027
  • UnitedHealth (UNH), Eli Lilly (LLY), Novo Nordisk (NOVOB DC) and AHIP were cited around insurer concerns, beneficiary access and next steps